ImmPACT Bio is a biotechnology startup that is pioneering the development of next-generation cell therapies to address unmet medical needs. The company operates in the healthcare market, specifically focusing on cancer treatment and autoimmune diseases.

The company's business model revolves around the development and commercialization of its proprietary ImmPACT Bio Platforms. These platforms utilize two key technologies: TGF-β CAR and iCAR. TGF-β CAR technology modifies T cell responses to overcome the immune suppressive environment often found in cancer, enabling more effective treatment. iCAR technology, on the other hand, allows for the specific targeting and killing of cancer cells while sparing healthy tissue. This technology has the potential to treat all solid tumors, offering a broad market opportunity.

ImmPACT Bio serves a diverse client base, primarily comprising patients with cancer and autoimmune diseases who have not found effective treatment through existing therapies. The company generates revenue through the development and sale of its innovative cell therapies.

In 2021, ImmPACT Bio merged with Kalthera Therapeutics, a move that likely expanded its research capabilities and market reach. The company prides itself on its team of pioneering scientists and its technologies designed to prevent antigen escape, overcome the immunosuppressive tumor environment, and cure autoimmune diseases.

Keywords: Biotechnology, Cell Therapies, Cancer Treatment, Autoimmune Diseases, TGF-β CAR Technology, iCAR Technology, Immune Suppressive Environment, Antigen Escape, ImmPACT Bio Platforms, Kalthera Therapeutics.